Eli Lilly (LLY) and Novo Nordisk (NVO) are slashing prices of their GLP-1 products in China as the rivalry in the booming obesity drug market there intensifies amid local competition, according to media reports.
Shanghai-based business news outlet Yicai reported
Follow us on Google for the latest stock news
